| Literature DB >> 28066436 |
Abstract
The hygiene hypothesis postulates that higher levels of cleanliness and improper exposure to microorganisms early in childhood could disturb the intestinal microbiome resulting in abnormal immune responses. Recently, more attention has been put on how a lack of sun exposure and consequently vitamin D deficiency could lead to less immune tolerance and aberrant immune responses. Moreover, vitamin D receptor (VDR) function has been positioned to be a critical aspect of immune response and gut homeostasis. Therefore, this review focuses on the role that the interaction between vitamin D, VDR function, and gut microbiome might have on autoimmune diseases in the context of the hygiene hypothesis. Literature shows that there is a high correlation between vitamin D deficiency, VDR dysfunction, gut microbiota composition, and autoimmune diseases. The biologically active form of vitamin D, 1,25(OH)2D3, serves as the primary ligand for VDRs, which have been shown to play a fundamental role in reducing autoimmune disease symptoms. Although the biological functions of VDR, the effects of its genetic variants, and the effects of epigenetic profiles in its promoter region are largely unknown in humans, studies in murine models are increasingly demonstrating that VDRs play a crucial role in attenuating autoimmune disease symptoms by regulating autophagy and the production of antimicrobial peptides, such cathelicidin and β-defensin, which are responsible for modifying the intestinal microbiota to a healthier composition. Remarkably, evidence shows that hormonal compounds and byproducts of the microbiota such as secondary bile acids might also activate VDR. Therefore, understanding the interaction between VDR and gut microbiota is of the utmost importance toward understanding the rise in autoimmune diseases in Western countries. We have gained insights on how the VDR functions affects inflammation, autophagy, and microbiota composition that could lead to the development of pathogenesis of autoimmune diseases, while confirming the role vitamin D and VDRs have in the context of hygiene hypothesis.Entities:
Keywords: Western lifestyle; autoimmune diseases; gut microbiota; hygiene hypothesis; vitamin D; vitamin D deficiency; vitamin D receptor
Year: 2016 PMID: 28066436 PMCID: PMC5179549 DOI: 10.3389/fimmu.2016.00627
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Western lifestyle factors that lead to autoimmunity diseases. The figure represents the main factors that contribute to the disruption of gut homeostasis and rise in autoimmune diseases in Western countries, such as stress, a hyper-hygienic lifestyle that includes deworming treatments at an early age, drinking chlorinated water (19), and excessive antibiotic treatments (34), the Western diet which is characteristically low in fiber and high in saturated fat (35), toxins (36), drugs (36–38), and vitamin D deficiency (39). Furthermore, Vitamin D deficiency and vitamin D receptor function have also been shown to disrupt gut homeostasis and consequently immune tolerance (40, 41). All of these factors can lead to intestinal dysbiosis, more susceptibility to pathogenic infections and intestinal permeability, which predispose to lipopolysaccharides translocation and trigger inflammatory immune responses such as TNF-α and IFN-γ (42). The loss of immune homeostasis can lead to food intolerances and allergies, which can subsequently lead to autoimmune disease development (19).
Figure 2Vitamin D. Vitamin D is synthesized from sun exposure or consumption of foods rich in vitamin D. The ultraviolet B rays from the sun at frequencies between 280 and 320 hit the skin where 7-dehydrocholesterol is converted into pre-vitamin D3 and is then isomerized into vitamin D3 or cholecalciferol (46). Vitamin D-binding protein then facilitates vitamin D3’s entrance into the dermal capillary bed (39). On the right of the figure, ingested vitamin D2 (ergocalciferol) from food or supplements is incorporated into chylomicrons, which enter the lymphatic system and blood. Once in the bloodstream, both vitamin D2 and vitamin D3 move to the liver where the enzyme cytochrome P450 hydroxylates both forms of the vitamin to 25(OH)D3. Then, the CYP27B1 further hydroxylates 25(OH)D3 into the active form of the vitamin [1,25(OH)2D3] in the kidneys (39). Unlike D2 or other vitamin D metabolites, vitamin D3 is the active form of vitamin D that binds to the vitamin D receptor (VDR), which is located in about 30 different tissues (47). The activated VDR binds to vitamin D responsive elements (VDREs) to form a heterodimer (48), which can regulate directly or indirectly the expression of ~3% of the mouse and human genomes (49).
Figure 3Vitamin D’s effect on the gut microbiota and immunity. The active form of vitamin D [1,25(OH)2D3] serves as the primary ligand for the vitamin D receptors (VDRs). The activated VDR binds to vitamin D responsive elements (VDREs) to regulate the expression of 3% of the genome (48). There are more than 1,000 genes with binding sites for VDRE, including antimicrobial peptides such as cathelicidin, β-defensin, cathelicidin antimicrobial peptide, and defensin β2 (33, 80). An activated VDR also regulates innate immune responses by controlling the genetic expression of toll-like receptor 2 (3), and nucleotide-binding oligomerization domain 2, which subsequently activates the transcription factor nuclear factor kappa light chain enhancer of activated B cells which induces defensin β2 gene expression (33). Activated VDR also plays a role in maintaining intestinal barrier function, which prevents lipopolysaccharides translocation and an ensuing inflammatory response by regulating the expression of the tight junction proteins zonulin occluden-1, zonulin occluden-2, claudin 2, and 12 in the intestine (75). VDRs can also inhibit the reduction in transepithelial electrical resistance by the pathogenic Escherichia coli O157:H7, which thus decreases intestinal permeability in epithelial cells (72). Furthermore, VDR promotes immune tolerance in the gut by inhibiting Th1 and Th17 cells proliferation, which produce IL-172 and IFN-γ production as dendritic cell-mediated IL-10 production, which increases regulatory T cell production promoting a T helper cell type 2 response (81, 82).
Effects vitamin D and its biologically active form [1,25(OH).
| Immunological effect | Reference |
|---|---|
| Promote the maturation, survival, and apoptosis of dendritic cells (DC), which is a key mechanism of the adaptive immune system | ( |
| Inhibit T cell proliferation, IL-2 and IFN-γ production, and T helper 1 (Th1) cells development | ( |
| Decrease B cells and antibody-secreting cells like IgG and IgM | ( |
| Promote regulatory T cell (Treg) proliferation by increasing C–C motif chemokine ligand 22 expression | ( |
| Regulate toll-like receptor (TLR)-2 expression | ( |
| Activate macrophages, DCs, and T cells | ( |
| Promote autoimmune homeostasis by stimulating Treg and inhibiting TLR8 activity | ( |
| Inhibits IFN-γ and IL-17 production and induce Tregs. Tregs, in turn, induce apoptosis, inhibit Th1 and T helper 17 immune responses, and produce IL-10 and TGF-β1 | ( |
| Regulate the expression of mRNAs for inflammatory cytokines such as IL-1, IL-10, IL-17, and IFN-γ, as well as levels of CD3+, CD4+, CD8+, and CD19+ | ( |
| Downregulate pro-inflammatory cytokines such as IL-1, IL-8, IL-, IL-17, and TNF-α | ( |
| Stimulate CD4(+) CD25(−) T cells and inhibit IFN-γ, IL-17, and IL-21. Work synergistically with IL-2 to produce CTLA-4 and FoxP3 Treg cells | ( |
| Upregulate the production of antimicrobial peptides such as cathelicidin and β-defensin and toll-like receptor 2 | ( |
| Increase cathelicidin antimicrobial peptide and β-defensin expression | ( |
| Regulate cathelicidin which activates the transcription of autophagy-related genes | ( |
| Induce nucleotide-binding oligomerization domain 2 in monocytic and epithelial cells which then stimulates NF-kB and defensin β2 | ( |
| Activate peroxisome proliferator activated receptor-gamma and alpha, glucocorticoids and androgens | ( |
| Inhibit growth of the parasite | ( |
| Control the expression of the tight junction proteins zonulin occluden-1, zonulin occluden-2, and can up regulate claudin 2 and 12 and down regulate cadherin-17 in the intestine | ( |
| Inhibits a reduction in transepithelial electrical resistance between intestinal epithelial cells by pathogenic | ( |
| Increase transepithelial electrical resistance and decreasing LPS levels in Caco-2 cells that were either incubated or not with DSS | ( |
| Attenuate irritable bowel disease through its anti-inflammatory properties and the prevention of dysbiosis | ( |